Cargando…
Clinical validation of controlled exposure to house dust mite in the environmental exposure unit (EEU)
RATIONALE: The Environmental Exposure Unit (EEU), a controlled allergen exposure model of allergic rhinitis (AR), has traditionally utilized seasonal allergens. We sought to clinically validate the use of house dust mite (HDM), a perennial allergen, in the HDM-EEU, a specially designed facility with...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995585/ https://www.ncbi.nlm.nih.gov/pubmed/33771217 http://dx.doi.org/10.1186/s13223-021-00536-3 |
_version_ | 1783669946798047232 |
---|---|
author | Hossenbaccus, Lubnaa Linton, Sophia Thiele, Jenny Steacy, Lisa Walker, Terry Malone, Crystal Ellis, Anne K. |
author_facet | Hossenbaccus, Lubnaa Linton, Sophia Thiele, Jenny Steacy, Lisa Walker, Terry Malone, Crystal Ellis, Anne K. |
author_sort | Hossenbaccus, Lubnaa |
collection | PubMed |
description | RATIONALE: The Environmental Exposure Unit (EEU), a controlled allergen exposure model of allergic rhinitis (AR), has traditionally utilized seasonal allergens. We sought to clinically validate the use of house dust mite (HDM), a perennial allergen, in the HDM-EEU, a specially designed facility within the larger EEU. METHODS: Forty-four HDM-allergic and eleven non-allergic participants were screened and deemed eligible for one of two 3-h exposure sessions in the HDM-EEU. Participants were exposed to a modest or higher HDM target, with blood and nasal brushing samples collected before and after allergen exposure. Symptomatic data, including Total Nasal Symptom Score (TNSS), Total Ocular Symptom Score (TOSS), Total Rhinoconjunctivitis Symptom Score (TRSS), and Peak Nasal Inspiratory Flow (PNIF) were collected at baseline, every 30 min until 3 h, on an hourly basis for up to 12 h, and at 24 h following the onset of HDM exposure. RESULTS: The modest and higher HDM target sessions respectively featured cumulative total particle counts of 156,784 and 266,694 particles (2.5–25 µm), Der f 1 concentrations of 2.67 ng/m(3) and 3.80 ng/m(3), and Der p 1 concentrations of 2.07 ng/m(3) and 6.66 ng/m(3). Allergic participants experienced an increase in symptoms, with modest target participants plateauing at 1.5 to 2 h and achieving a mean peak TNSS of 5.74 ± 0.65, mean peak TOSS of 2.47 ± 0.56, and mean peak TRSS of 9.16 ± 1.32. High HDM-target allergics reached a mean peak TNSS of 8.17 ± 0.71, mean peak TOSS of 4.46 ± 0.62, and mean peak TRSS of 14.08 ± 1.30 at 3 h. All allergic participants’ symptoms decreased but remained higher than baseline after exiting the HDM-EEU. Sixteen participants (37.2%) were classified as Early Phase Responders (EPR), eleven (25.6%) as protracted EPR (pEPR), seven (16.3%) as Dual Phase Responders (DPR), and nine (20.9%) as Poor Responders (PR). Allergic participants experienced significant percent PNIF reductions at hours 2 and 3 compared to healthy controls. Non-allergics were asymptomatic during the study period. CONCLUSIONS: The HDM-EEU is an appropriate model to study HDM-induced AR as it can generate clinically relevant AR symptoms amongst HDM-allergic individuals. |
format | Online Article Text |
id | pubmed-7995585 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-79955852021-03-26 Clinical validation of controlled exposure to house dust mite in the environmental exposure unit (EEU) Hossenbaccus, Lubnaa Linton, Sophia Thiele, Jenny Steacy, Lisa Walker, Terry Malone, Crystal Ellis, Anne K. Allergy Asthma Clin Immunol Research RATIONALE: The Environmental Exposure Unit (EEU), a controlled allergen exposure model of allergic rhinitis (AR), has traditionally utilized seasonal allergens. We sought to clinically validate the use of house dust mite (HDM), a perennial allergen, in the HDM-EEU, a specially designed facility within the larger EEU. METHODS: Forty-four HDM-allergic and eleven non-allergic participants were screened and deemed eligible for one of two 3-h exposure sessions in the HDM-EEU. Participants were exposed to a modest or higher HDM target, with blood and nasal brushing samples collected before and after allergen exposure. Symptomatic data, including Total Nasal Symptom Score (TNSS), Total Ocular Symptom Score (TOSS), Total Rhinoconjunctivitis Symptom Score (TRSS), and Peak Nasal Inspiratory Flow (PNIF) were collected at baseline, every 30 min until 3 h, on an hourly basis for up to 12 h, and at 24 h following the onset of HDM exposure. RESULTS: The modest and higher HDM target sessions respectively featured cumulative total particle counts of 156,784 and 266,694 particles (2.5–25 µm), Der f 1 concentrations of 2.67 ng/m(3) and 3.80 ng/m(3), and Der p 1 concentrations of 2.07 ng/m(3) and 6.66 ng/m(3). Allergic participants experienced an increase in symptoms, with modest target participants plateauing at 1.5 to 2 h and achieving a mean peak TNSS of 5.74 ± 0.65, mean peak TOSS of 2.47 ± 0.56, and mean peak TRSS of 9.16 ± 1.32. High HDM-target allergics reached a mean peak TNSS of 8.17 ± 0.71, mean peak TOSS of 4.46 ± 0.62, and mean peak TRSS of 14.08 ± 1.30 at 3 h. All allergic participants’ symptoms decreased but remained higher than baseline after exiting the HDM-EEU. Sixteen participants (37.2%) were classified as Early Phase Responders (EPR), eleven (25.6%) as protracted EPR (pEPR), seven (16.3%) as Dual Phase Responders (DPR), and nine (20.9%) as Poor Responders (PR). Allergic participants experienced significant percent PNIF reductions at hours 2 and 3 compared to healthy controls. Non-allergics were asymptomatic during the study period. CONCLUSIONS: The HDM-EEU is an appropriate model to study HDM-induced AR as it can generate clinically relevant AR symptoms amongst HDM-allergic individuals. BioMed Central 2021-03-26 /pmc/articles/PMC7995585/ /pubmed/33771217 http://dx.doi.org/10.1186/s13223-021-00536-3 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Hossenbaccus, Lubnaa Linton, Sophia Thiele, Jenny Steacy, Lisa Walker, Terry Malone, Crystal Ellis, Anne K. Clinical validation of controlled exposure to house dust mite in the environmental exposure unit (EEU) |
title | Clinical validation of controlled exposure to house dust mite in the environmental exposure unit (EEU) |
title_full | Clinical validation of controlled exposure to house dust mite in the environmental exposure unit (EEU) |
title_fullStr | Clinical validation of controlled exposure to house dust mite in the environmental exposure unit (EEU) |
title_full_unstemmed | Clinical validation of controlled exposure to house dust mite in the environmental exposure unit (EEU) |
title_short | Clinical validation of controlled exposure to house dust mite in the environmental exposure unit (EEU) |
title_sort | clinical validation of controlled exposure to house dust mite in the environmental exposure unit (eeu) |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995585/ https://www.ncbi.nlm.nih.gov/pubmed/33771217 http://dx.doi.org/10.1186/s13223-021-00536-3 |
work_keys_str_mv | AT hossenbaccuslubnaa clinicalvalidationofcontrolledexposuretohousedustmiteintheenvironmentalexposureuniteeu AT lintonsophia clinicalvalidationofcontrolledexposuretohousedustmiteintheenvironmentalexposureuniteeu AT thielejenny clinicalvalidationofcontrolledexposuretohousedustmiteintheenvironmentalexposureuniteeu AT steacylisa clinicalvalidationofcontrolledexposuretohousedustmiteintheenvironmentalexposureuniteeu AT walkerterry clinicalvalidationofcontrolledexposuretohousedustmiteintheenvironmentalexposureuniteeu AT malonecrystal clinicalvalidationofcontrolledexposuretohousedustmiteintheenvironmentalexposureuniteeu AT ellisannek clinicalvalidationofcontrolledexposuretohousedustmiteintheenvironmentalexposureuniteeu |